Skip to main content
OpenTrials
Completed

NCT Number: NCT04044495

Sleep, Rhythms and Risk of Alzheimer's Disease

Alterations in sleep and the sleep / wake cycle, which are particularly common in Alzheimer's disease patients, could represent an early biomarker for cognitive decline and onset of dementia . Moreover, these disturbances in activity rhythms and sleep patterns represent modifiable factors and therefore potential targets for the prevention of certain neurodegenerative disorders.

The main objective of this study will be to test the hypothesis that elderly people without major cognitive impairment who have circadian rhythm disorders of the sleep / wake cycle have structural and / or functional abnormalities in the central nervous system and more specifically of the hippocampal function which could represent a risk factor for the occurrence of cognitive impairment. Indeed, although many studies in both humans and animals suggest the existence of links between sleep alterations and age-related cognitive impairment, the causality of these observations is still not clear.

This description of the anatomical and functional substratum of sleep / wake cycle alterations occurring in an elderly population will be based on joint analysis of multimodal brain imaging (MRI) and neuropsychology actimetry data. The SoRyMA-AMImage 3 protocol will correspond to the 2nd actimetry measurement point and the 3rd MRI measurement point of a larger population-based cohort AMImage.

This project will collect data from the sleep / wake cycle (actimetry) from a sample of 100 patients included in AMI / AMImage 2 and relate them to brain imaging data (MRI). The main objective of the protocol is the evaluation of the link between changes in sleep and cycle parameters during aging and hippocampal functioning (through fMRI and neuropsychological score of hippocampal dependant tasks). The actimetry variables measured at the two follow-up (4 years apart) will make it possible to measure the degradation of the sleep and cycle parameters (through the reduction of sleep duration, sleep time, increase in sleep fragmentation and decrease in the relative amplitude of the rhythm).

This framework will provide access to a very large amount of data that can be cross-referenced with actimetry data; the longitudinal character of this data collected over a decade will also make it possible to work on the evolution of the actimetry parameters and its relationship with the cognitive and clinical evolution of the subjects. Thus, these data will make it possible to study the prognostic value of the analyzed actimetry parameters in association with very complete clinical and neuropsychological data.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Sleep Tauopathies

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU de Bordeaux

Bordeaux, 33 076, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Belonging to AMImage 2 cohort and preferentially belonging to subjects included in the first actimetric assessment. AMI subjects have been selected based on Mutualité Sociale Agricole of Gironde (agricultural Health Insurance system database as followed :
  • >65 years old
  • Retired from agriculture
  • Living in Gironde countryside
  • Being affiliated to the French Farmers Health Insurance
  • Signed Informed Consent

Exclusion criteria

  • Left Handed subjects
  • Severe dementia (MMSE<13)
  • Stroke
  • Parkinson's disease
  • MRI contraindication
  • Health state not allowing displacement to the hospital
  • Person under gardianship and not able to give its informed consent

Treatment and study plan

Multimodal brain imaging (MRI)

Other

Multimodal brain imaging (MRI)

Actimetry

Other

7 days actimetry

Sleep Diary

Other

7 days Record of sleep and wake cycle

Primary outcomes

  1. Bold Signal

    Time frame: Day 1

    Bold Signal on Magnetic Resonance Imaging (MRI)

Secondary outcomes

  1. Pittsburgh Sleep Quality Index (PSQI) Score

    Time frame: Day 1

    seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21). Higher scores indicate worse sleep quality

  2. Mannheim Dream questionnaire (MADRE)

    Time frame: Day 1

    MADRE questionnaire evaluates dream recall frequency, emotional aspects of dreams (intensity and tonality), nightmares, lucid dreaming, attitude towards dreams, effects of dreams on waking life and dream literature reading and has been demonstrated to show high retest reliability

  3. Epworth Sleepiness Scale

    Time frame: Day 1

    The test is a list of eight situations in which is rate the tendency to become sleepy on a scale of 0, no chance of dozing, to 3, high chance of dozing

  4. Toronto Alexithymia Scale (TAS-20)

    Time frame: Day 1

    The TAS-20 is a self-report scale that is comprised of 20 items.

    The TAS-20 has 3 subscales:

    • Difficulty Describing Feelings subscale is used to measure difficulty describing emotions. 5 items.
    • Difficulty Identifying Feeling subscale is used to measure difficulty identifying emotions. 7 items.
    • Externally-Oriented Thinking subscale is used to measure the tendency of individuals to focus their attention externally. 8 items.

    Items are rated using a 5-point Likert scale whereby 1 = strongly disagree and 5 = strongly agree.

    The total alexithymia score is the sum of responses to all 20 items, while the score for each subscale factor is the sum of the responses to that subscale. The TAS-20 uses cutoff scoring: equal to or less than 51 = non-alexithymia, equal to or greater than 61 = alexithymia. Scores of 52 to 60 = possible alexithymia.

  5. Positive and Negative Affective Scale (PANAS)

    Time frame: Day 1

    The PANAS Scale or Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire. The test comprises 20 terms, with ten focusing on a positive emotion and the other ten focusing on a negative emotion. The final score of the PANAS Scale / Positive and Negative Affect Schedule (PANAS) test is the sum of the 10 terms on the positive scale and the sum of the 10 terms on the negative scale. The value assigned is positive for answers on the positive scale and negative for answers on the negative scale.

  6. Emotional Regulation Questionnaire (ERQ)

    Time frame: Day 1

    10-item scale designed to measure respondents' tendency to regulate their emotions in two ways: (1) Cognitive Reappraisal and (2) Expressive Suppression. Respondents answer each item on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree). The scoring takes the average of all the scores.

  7. Actimetry

    Time frame: Up to 7 days

    Automatically record of waking and sleeping periods on 7 consecutive days

  8. Sleep diary

    Time frame: Up to 7 days

    Series of questions for each 24-hour period with a collection of bedtime, wake-up time, possible night awakenings or even naps

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Registry information

Official study title

"Sleep, Rhythms and Risk of Alzheimer's Disease: a Daily Life Actigraphic Assessment and MRI Study" "SoRyMA - AMImage3"

Acronym: AMImage3

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Aug 5, 2019
Registry last updated
Jun 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.